|
End-of-day quote
Taiwan S.E.
2026-08-17
|
5-day change | 1st Jan Change | ||
| 55.90 TWD | 0.00% |
|
-1.41% | +4.40% |
| Market Cap | 10.99B 345M 298M 279M 255M 479M 32.99B 485M 3.28B 1.28B 16.53B 1.3B 1.27B 54.98B | P/E 2024 |
12.6x | P/E 2025 | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 9.55B 300M 259M 243M 221M 416M 28.68B 422M 2.85B 1.12B 14.37B 1.13B 1.1B 47.79B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.29x |
| Free-Float |
44.21% | Yield 2024 |
4.52% | Yield 2025 | 3.4% |
| 1 week | -1.41% | ||
| Current month | -1.41% | ||
| 1 month | -3.17% | ||
| 3 months | -0.18% | ||
| 6 months | +1.30% | ||
| Current year | +4.40% |
| 1 week | 55.7 |  | 56.8 |
| 1 month | 55.7 | | 58.55 |
| Current year | 53.55 | | 60.55 |
| 1 year | 48.64 | | 60.55 |
| 3 years | 46.55 | | 72.18 |
| 5 years | 33.45 | | 72.36 |
| 10 years | 24.86 | | 72.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zi Ting Fan
CEO | Chief Executive Officer | - | 2006-05-29 |
Reynold Hsu
DFI | Director of Finance/CFO | - | 2019-07-15 |
Wei Jen Chen
PRN | Corporate Officer/Principal | - | 2001-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Chin Tsai Fan
CHM | Chairman | - | 1967-06-29 |
Yuan Te Li
BRD | Director/Board Member | - | 2012-06-05 |
Tsui Wen Yeh
BRD | Director/Board Member | - | 2002-05-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -1.41% | +9.02% | -2.71% | 345M | |
| +0.25% | -3.96% | +68.73% | +120.06% | 1,055B | |
| +0.78% | +0.21% | +48.53% | +50.78% | 632B | |
| +0.35% | +0.95% | +21.11% | +66.86% | 442B | |
| +0.28% | -4.56% | +39.10% | +38.05% | 351B | |
| +0.78% | -2.68% | +24.03% | +37.32% | 290B | |
| +0.87% | -3.59% | -0.28% | +7.12% | 243B | |
| +1.00% | +0.52% | +41.46% | +58.95% | 227B | |
| -0.78% | -4.49% | -10.28% | -54.13% | 200B | |
| +0.40% | +4.40% | +17.36% | +81.59% | 172B | |
| Average | +0.39% | -1.17% | +25.88% | +40.39% | 361.29B | |
| Weighted average by Cap. | +0.44% | -1.70% | +39.71% | +63.88% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 6.79B 213M 184M 173M 157M 296M 20.38B 300M 2.02B 793M 10.21B 800M 783M 33.97B | 7.02B 221M 190M 179M 163M 306M 21.09B 310M 2.09B 820M 10.56B 828M 810M 35.14B |
| Net income | 881M 27.65M 23.87M 22.39M 20.4M 38.35M 2.64B 38.88M 263M 103M 1.32B 104M 102M 4.41B | 928M 29.13M 25.15M 23.59M 21.49M 40.4M 2.79B 40.96M 277M 108M 1.4B 109M 107M 4.64B |
| Net Debt | -1.24B -39.05M -33.71M -31.63M -28.81M -54.16M -3.73B -54.91M -371M -145M -1.87B -147M -143M -6.22B | -1.44B -45.1M -38.93M -36.53M -33.27M -62.56M -4.31B -63.42M -428M -168M -2.16B -169M -166M -7.19B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-17 | NT$55.90 | 0.00% | 130,882 |
| 26-08-14 | NT$55.90 | -0.89% | 362,254 |
| 26-08-13 | NT$56.40 | -0.18% | 256,285 |
| 26-08-12 | NT$56.50 | +0.18% | 218,541 |
| 26-08-11 | NT$56.40 | -0.53% | 129,959 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1720 Stock
Select your edition
All financial news and data tailored to specific country editions
